CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (Nasdaq: IDIX), announced today that
Ronald C. Renaud, Jr. has been
elected as President, Chief Executive Officer and a member of the
board of directors of the company. Mr. Renaud has served as
the company's Chief Financial Officer and Treasurer since
June 2007 and Chief Business Officer
since June 2010. Prior to
joining Idenix in 2007, Mr. Renaud served as Senior Vice President
and Chief Financial Officer of Keryx Biopharmaceuticals.
Prior to his position at Keryx, he spent several years as a
biotechnology analyst for leading investment banks including Bear
Stearns, Schwab Soundview and JPMorgan. Mr. Renaud also spent
more than 5 years at Amgen, where he held positions in clinical
research, investor relations and finance. Mr. Renaud holds a
B.A. from St. Anselm College and an
M.B.A. from the Marshall School of Business at the University of Southern California.
Jean-Pierre Sommadossi, Ph.D., has resigned as President,
Chief Executive Officer and Chairman and a member of the board of
directors of the company, in order to pursue other interests in the
biotechnology field. Dr. Sommadossi was the principal
founder of Idenix and had served as the chairman of the board of
directors since its inception in 1998. Dr. Sommadossi had
served as President and Chief Executive Officer since
November 2000.
"Jean-Pierre has guided development of Idenix since inception
and the company has made considerable progress under his
leadership," said Thomas R. Hodgson,
lead director of the board of directors of the company. "We wish
Jean-Pierre every success in his future endeavors. We are
extremely pleased to have Ron
Renaud, an experienced and capable executive who has worked
closely with the board of directors, move into the position of
President and CEO. The board of directors believes Ron is uniquely
qualified to advance Idenix into the next phase of its
evolution."
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company engaged in the discovery and development
of drugs for the treatment of human viral diseases. Idenix's
current focus is on the treatment of hepatitis C virus.
Idenix Pharmaceuticals
Contacts:
|
|
Kelly Barry (617) 995-9033
(media)
|
|
Jonae Barnes (617) 224-4485
(investors)
|
|
|
SOURCE Idenix Pharmaceuticals, Inc.
Copyright . 28 PR Newswire